Literature DB >> 11154039

Bilateral transient hearing loss associated with vincristine therapy: case report.

I Aydogdu1, O Ozturan, I Kuku, E Kaya, A Sevinc, R Yildiz.   

Abstract

Vincristine, adriamycin, and dexamethasone (VAD) chemotherapy protocol is first-choice treatment in newly diagnosed multiple myeloma patients in many centers. Sudden hearing loss associated with vincristine therapy is a rarely observed event in the VAD protocol. We describe a 69-year old male patient diagnosed with multiple myeloma 7 months ago who developed sudden bilateral hearing loss related to vincristine therapy. This uncommon adverse effect of vincristine is discussed and the literature reviewed.

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 11154039     DOI： 10.1179/joc.2000.12.6.530

Source DB:  PubMed          Journal:  J Chemother        ISSN： 1120-009X            Impact factor:   1.714


  4 in total

Review 1.  Drug-Induced Ototoxicity: Diagnosis and Monitoring.

Authors:  Kathleen C M Campbell; Colleen G Le Prell
Journal:  Drug Saf       Date:  2018-05       Impact factor: 5.606

2.  Hair cell toxicity in anti-cancer drugs: evaluating an anti-cancer drug library for independent and synergistic toxic effects on hair cells using the zebrafish lateral line.

Authors:  Yoshinobu Hirose; Julian A Simon; Henry C Ou
Journal:  J Assoc Res Otolaryngol       Date:  2011-07-06

3.  Myeloma cast nephropathy presenting as acute onset bilateral reversible hearing loss.

Authors:  Mufazzal Ahmad
Journal:  Int Urol Nephrol       Date:  2007-06-07       Impact factor: 2.370

4.  Replication of TPMT and ABCC3 genetic variants highly associated with cisplatin-induced hearing loss in children.

Authors:  K Pussegoda; C J Ross; H Visscher; M Yazdanpanah; B Brooks; S R Rassekh; Y F Zada; M-P Dubé; B C Carleton; M R Hayden
Journal:  Clin Pharmacol Ther       Date:  2013-04-10       Impact factor: 6.875
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.